Lacosamide

  Cat. No.:  DC8797   Featured
Chemical Structure
175481-36-4
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Lacosamide (Vimpat; Erlosamide) is a medication developed for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.
Cas No.: 175481-36-4
Chemical Name: Lacosamide
Synonyms: LACOSAMIDE;(2R)-2-acetamido-N-benzyl-3-methoxy-propanamide;(2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide;ADD 243037;Erlosamide;Harkoseride;SPM 927;(R)-2-Acetamido-N-benzyl-3-methoxypropanamide;Lacosamide solution;Erlosamide [INN];S1253_Selleck;Vimpat;(2R)-N-benzyl-2-acetaMido-3-MethoxypropanaMide;(2R)-2-acetamido-N-benzyl-3-methoxypropanamide;ADD 234037;563KS2PQY5;Propanamide, 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-;(2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide;(R)-2-Acetylamino-N-benzyl-3-methoxy-propionamide;harkeroside;Lacosamide [USAN:INN:BAN];ADD 2;HY-13015;Tox21_113857;LACOSAMIDE [VANDF];LACOSAMIDE (MART.);(R)-N-benzyl-2-acetamido-3-methoxypropanamide;LACOSAMIDE CV (USP-RS);CHEBI:135939;LACOSAMIDE [EP MONOGRAPH];Lacosamide 1.0 mg/ml in Acetonitrile;N03AX18;DB06218;Lacosamide- Bio-X;(R)-2-acetamido-N-benzyl-3-methoxypropionamide.;DTXSID1057666;Lacosamide;LACOSAMIDE [WHO-DD];BDBM50300204;N~2~-Acetyl-N-benzyl-O-methyl-D-serinamide;CS-0529;BL164605;Lacosamida;SPM-929;GTPL7472;(2R)-2-acetamido-3-methoxy-N-(phenylmethyl)propanamide;KS-1227;AB01559947-01;(r)-lacosamide 1;LACOSAMIDE [ORANGE BOOK];UNII-563KS2PQY5;ADD-234037;DTXCID2031455;Lacosamide (JAN/USAN/INN);175481-36-4;(R)-2-Acetylamino-N-benzyl-3-methoxypropionamide;MOTPOLY;BB 0260890;VPPJLAIAVCUEMN-GFCCVEGCSA-N;Lacosamide [USAN];LACOSAMIDE [MART.];LACOSAMIDE [USP MONOGRAPH];Vimpat (TN);ertosamide;Motpoly XR;SR-01000942286;lacosamidum;Lacosamide cv;Lacosamide Oral Solution;(R)-2-acetamido-N-benzyl-3-methoxypropionamide;LACOSAMIDE [INN];SCHEMBL35330;LACOSAMIDE (USP MONOGRAPH);LACOSAMIDE (EP MONOGRAPH);CHEMBL58323;SPM-927;(2R)-2-acetylamino-N-benzyl-3-methoxypropanamide;(R)-N-Benzyl-2-acetamido-3-methoxypropionamide;NCGC00253740-01;A3897;DEA No. 2746;AR-270/11402703;LQO;LACOSAMIDE [MI];ADD243037;(R)-2-acetamido-N-benzyl-3-methoxypropanamide;2-(Acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-;D07299;AM808141;()-(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide;ADD-243037;AC-22750;(R)-N-benzyl 2-acetamido-3-methoxypropionamide;SPM927;CAS-175481-36-4;LACOSAMIDE [EMA EPAR];SR-01000942286-1;LACOSAMIDE [USP-RS];Lacosamide racemate;Q420077;(+)-(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide;BCP02197;LACOSAMIDE [JAN];(R)-N-benzyl 2-acetamido-3-methoxypropionamide,;AKOS005146274;ViMpat;LacosaMide (1.0Mg/ML in Acetonitrile)
SMILES: O(C([H])([H])[H])C([H])([H])[C@]([H])(C(N([H])C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])=O)N([H])C(C([H])([H])[H])=O
Formula: C13H18N2O3
M.Wt: 250.2936
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Lacosamide is a functionalized amino acid that produces activity in the maximal electroshock seizure (MES) test, that, like some other antiepileptic drugs (AEDs), are believed to act through voltage-gated sodium channels. Lacosamide enhances the slow inactivation of voltage-gated sodium channels without affecting the fast inactivation of voltage-gated sodium channels. This inactivation prevents the channel from opening, helping end the action potential. Many antiepileptic drugs, like carbamazepine or lamotrigine, slow the recovery from inactivation and hence reduce the ability of neurons to fire action potentials.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC8797 Lacosamide Lacosamide (Vimpat; Erlosamide) is a medication developed for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.
X